The Application Notebook
Toxicology Laboratory at the Veterans Administration, Portland, Oregon, USA, Agilent Technologies
A fast, cost-effective, and highly sensitive method was developed for the determination of five barbiturates with four internal standards (ISTDs) in urine using an Agilent 6430 Triple Quadrupole LC–MS system and an Agilent Poroshell 120 EC-C18 column. The sample of urine was extracted using an Agilent SPEC-C18AR cartridge. Results indicate that the method effectively extracts the selected barbiturates from urine, resolving the target compounds and the ISTDs in 8.5 min. Though amobarbital and pentobarbital differ only in the position of a methyl group and are, therefore, difficult to separate, their resolution is sufficient for routine analysis.
All compounds were purchased from Cerilliant Corporation, Round Rock, Texas, United States.
1. Begin by centrifuging the urine sample at 2800 rpm for 5 min.
2. Pipette 1 mL of centrifuged sample into a 13 mm × 100 mm borosilicate glass tube.
3. Add exactly 35 µL of the working deuterated internal standard (butalbital-D5, pentobarbital-D5, secobarbital-D5, and phenobarbital-D5).
4. Pipette 500 µL 0.1 M phosphate buffer into the sample. The phosphate buffer is prepared by adding 13.61 g KH2PO4 into 800 mL water, adjusting to pH 6.0 with KOH, then making the volume up to 1 L.
5. Use a vacuum chamber with the Agilent SPEC-C18AR cartridge for extraction. Condition the cartridge with 0.2 mL of MeOH and load the sample solution.
6. Wash the column with 0.5 mL water and dry for 1 min.
7. Elute the cartridge with 1 mL 90:10 hexane:ethyl acetate mixture.
8. Collect the eluent and dry the sample under nitrogen gas at 35 °C.
9. Reconstitute with 0.5 mL 90:10 water:acetonitrile mixture.
The method was performed on the Agilent 1260 Infinity LC with a 6430 Triple Quadrupole LC–MS.
Column: Agilent Poroshell 120 EC-C18, 2.1 mm × 100 mm, 2.7 µm (p/n 695775-902)
Sample preparation: Agilent SPEC-C18CR, 3 mL, 15 mg (p/n A5321920); Eluent A, 5 mM ammonium acetate; Eluent B, LC–MS grade acetonitrile
ESI drying gas: 350 °C, 10 L/min
Nebulizer: 40 psi
Negative ionization mode
Capillary: 4000 V, DEMV 400
Note: If using an instrument that is not configured for low delay volume, use about 1 minute initial hold.
Figure 1: MRM chromatograms of barbiturates and internal standards using an Agilent Poroshell 120 EC-C18 column.
The superficially porous particles of Poroshell 120 have nearly identical efficiency as sub-2 µm totally porous materials and therefore can be used to provide similarly fast and high resolution analyses at a lower pressure. A separation of the nine barbiturates in 8.5 min was achieved on the column with a gradient method (Figure 1). Reasonable resolution was achieved between the standard components, except for pentobarbital and amobarbital. These are the isomers with the same product ions, which could not be identified by MS. However, they still have some separation on Poroshell 120 EC-C18 and the resolution for amobarbital and pentobarbital is sufficient for routine analysis.
The stock standards solution, containing phenobarbital, butalbital, pentobarbital, amobarbital, and secobarbital, was diluted to a series of linear solutions of 3000 ng/mL, 1500 ng/mL, and 150 ng/mL. In each solution, the ISTDs of phenobarbital-d5, butalbital-d5, pentobarbital-d5, and secobarbital-d5 were made up to a concentration of 1000 ng/mL. The method showed excellent linearity, being very close to 1.0 (from 0.9995 to 0.99998). For more information, including calibration curves, see the full-length application note, Agilent publication 5991-2596EN.
Table 1: Optimized MRM conditions.
The standards, at a concentration of 150 ng/mL, were spiked into the urine sample blank and processed with the solid-phase extraction (SPE) procedure. The recoveries were calculated and are shown in Table 2.
Table 2: Recoveries of barbiturates from a urine sample with SPE.
A method was developed for the extraction and separation of barbiturates using an Agilent SPEC-C18AR for sample extraction and an Agilent Poroshell 120 EC-C18 column for separation. The sample preparation method effectively extracted the selected barbiturates from urine, with sufficient recoveries and precision. The column provided good selectivity and good resolution for these compounds. The method developed on the Agilent 6430 Triple Quadrupole LC–MS system was suitable for quantitative analysis of these compounds in urine, especially at low concentration levels.
Agilent Technologies
2850 Centerville Road Wilmington, Delaware 19808, USA
Website: www.agilent.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.